Dapagliflozin Modulates the Fecal Microbiota in a Type 2 Diabetic Rat Model

Background: The gut microbiota is recognized as a major modulator of metabolic disorders such as type 2 diabetes. Dapagliflozin, sodium glucose cotransporter 2 inhibitors (SGLT2i), enhances renal glucose excretion, and lowers blood glucose levels. The study aimed to determine the effects of dapaglif...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Mei, Shi, Fang-Hong, Liu, Wen, Zhang, Min-Chun, Feng, Ri-Lu, Qian, Cheng, Liu, Wei, Ma, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7707060/
https://www.ncbi.nlm.nih.gov/pubmed/33312157
http://dx.doi.org/10.3389/fendo.2020.00635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7707060/
https://www.ncbi.nlm.nih.gov/pubmed/33312157
http://dx.doi.org/10.3389/fendo.2020.00635

Ejemplares similares